T-cell prolymphocytic leukemia medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 9: Line 9:
==Medical Therapy==
==Medical Therapy==


T-cell prolymphocytic leukemia responds better when combinations of chemotherapy drugs are used. Some combinations that may be used are:<ref name=T-PLL>{{cite web | title = Canadian Cancer Society| url =http://www.cancer.ca/en/cancer-information/cancer-type/non-hodgkin-lymphoma/non-hodgkin-lymphoma/types-of-nhl/prolymphocytic-leukemias/?region=on }}</ref>
===Chemotherapy===
 
T-cell prolymphocytic leukemia responds better when combinations of [[chemotherapy]] drugs are used. Some combinations that may be used are:<ref name=T-PLL>{{cite web | title = Canadian Cancer Society| url =http://www.cancer.ca/en/cancer-information/cancer-type/non-hodgkin-lymphoma/non-hodgkin-lymphoma/types-of-nhl/prolymphocytic-leukemias/?region=on }}</ref>


* CVP – [[Cyclophosphamide]], [[vincristine]] and [[prednisone]].
* CVP – [[Cyclophosphamide]], [[vincristine]] and [[prednisone]].
Line 23: Line 25:
===Biological therapy===
===Biological therapy===


Monoclonal antibodies are a type of biological therapy that has been effective in treating certain types of [[leukemias]]. These drugs may be used alone or in combination with chemotherapy to treat prolymphocytic leukemia.
Monoclonal antibodies are a type of [[biological therapy]] that has been effective in treating certain types of [[leukemias]]. These drugs may be used alone or in combination with chemotherapy to treat prolymphocytic leukemia.


* [[Alemtuzumab]] seems to be particularly effective in treating T-cell prolymphocytic leukemia. It may be used in people whose [[lymphoma]] is no longer responding to chemotherapy drugs like [[fludarabine]].
* [[Alemtuzumab]] seems to be particularly effective in treating T-cell prolymphocytic leukemia. It may be used in people whose [[lymphoma]] is no longer responding to chemotherapy drugs like [[fludarabine]].

Revision as of 15:26, 30 September 2015

T-cell prolymphocytic leukemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating T-cell Prolymphocytic Leukemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

T-cell prolymphocytic leukemia medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of T-cell prolymphocytic leukemia medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on T-cell prolymphocytic leukemia medical therapy

CDC on T-cell prolymphocytic leukemia medical therapy

T-cell prolymphocytic leukemia medical therapy in the news

Blogs on T-cell prolymphocytic leukemia medical therapy

Directions to Hospitals Treating T-cell prolymphocytic leukemia

Risk calculators and risk factors for T-cell prolymphocytic leukemia medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Carlos A Lopez, M.D. [2]

Overview

Medical Therapy

Chemotherapy

T-cell prolymphocytic leukemia responds better when combinations of chemotherapy drugs are used. Some combinations that may be used are:[1]

Other chemotherapy drugs (purine analogues) are often used to treat T-cell prolymphocytic leukemia are:

Biological therapy

Monoclonal antibodies are a type of biological therapy that has been effective in treating certain types of leukemias. These drugs may be used alone or in combination with chemotherapy to treat prolymphocytic leukemia.

  • Alemtuzumab seems to be particularly effective in treating T-cell prolymphocytic leukemia. It may be used in people whose lymphoma is no longer responding to chemotherapy drugs like fludarabine.

References

  1. "Canadian Cancer Society".

Template:WH Template:WS